Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Sable, Suraj B ^a   Cheruvu, Mani ^a   Nandakumar, Subhadra ^a   Sharma, Sunita ^b   Bandyopadhyay, Kakali ^c   Kellar, Kathryn L ^c   Posey, James E ^a   Plikaytis, Bonnie B ^a   Amara, Rama Rao ^b   Shinnick, Thomas M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE PROLINE ANTIGEN; BCG VACCINE; CULTURE FILTRATE PROTEIN 10; CYTOKINE; PROTEIN AG85A; PROTEIN AG85B; PROTEIN DNAK; PROTEIN GROEL; PROTEIN GROES; PROTEIN MPT 64; PROTEIN PST S1; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ALANINE; BACTERIAL ANTIGEN; GAMMA INTERFERON; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CERVICAL LYMPH NODE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; FEMALE; LUNG PARENCHYMA; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; THROMBOSIS PREVENTION; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; METABOLISM; METHODOLOGY; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; SPECIES DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; TIME; VACCINATION;

MUS; MYCOBACTERIUM TUBERCULOSIS;

ADMINISTRATION, INTRANASAL; ALANINE; ANIMALS; ANTIGENS, BACTERIAL; BCG VACCINE; FEMALE; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE; SPECIES SPECIFICITY; T-LYMPHOCYTES; TIME FACTORS; TUBERCULOSIS; VACCINATION;

EID: 79960722944     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022718     Document Type: Article

References (66)

1. Dye C, Williams BG, (2010) The population dynamics and control of tuberculosis. Science 328: 856-861.
2. Andersen P, Doherty TM, (2005) The success and failure of BCG- implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.
3. Russell DG, Barry CE, Flynn JL, (2010) Tuberculosis: What We Don't Know Can, and Does, Hurt Us. Science 328: 852-856.
4. Griffiths G, Nystroem B, Sable SB, Khuller GK, (2010) Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol 8: 827-834.
5. Kaufmann SH, (2010) Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33: 567-577.
6. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S, (2007) Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb) 87: 257-266.
7. Giri PK, Khuller GK, (2008) Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev Vaccines 7: 1341-1356.
8. Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B, (2006) Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Deliv 3: 87-95.
9. Hokey DA, Misra A, (2011) Aerosol vaccines for tuberculosis: a fine line between protection and pathology. Tuberculosis (Edinb) 91: 82-85.
10. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT, (1990) Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 161: 487-492.
11. Rook GA, Dheda K, Zumla A, (2005) Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? Vaccine 23: 2115-2120.
12. Kaufmann SH, (2006) Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 6: 699-704.
13. Falero-Diaz G, Challacombe S, Banerjee D, Douce G, Boyd A, et al. (2000) Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18: 3223-3229.
14. Chen L, Wang J, Zganiacz A, Xing Z, (2004) Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun 72: 238-246.
15. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, et al. (2006) Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 177: 6353-6360.
16. Carpenter ZK, Williamson ED, Eyles JE, (2005) Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J Control Release 104: 67-77.
17. Kohama H, Umemura M, Okamoto Y, Yahagi A, Goga H, et al. (2008) Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in infected mice. Vaccine 26: 924-932.
18. Hamasur B, Haile M, Pawlowski A, Schroder U, Williams A, et al. (2003) Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 21: 4081-4093.
19. D'Souza S, Rosseels V, Denis O, Tanghe A, De Smet N, et al. (2002) Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 70: 3681-3688.
20. Lorenzi JCC, Trombone APF, Rocha CD, Almeida LP, Lousada RL, et al. (2010) Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis. BMC Biotechnol 10: 77.
21. Parida SK, Huygen K, Ryffel B, Chakraborty T, (2005) Novel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof of principle in TB mouse model. Ann N Y Acad Sci 1056: 366-378.
22. Ciabattini A, Pettini E, Andersen P, Pozzi G, Medaglini D, (2008) Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria. Infect Immun 76: 5817-5825.
23. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.
24. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, et al. (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173: 6357-6365.
25. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, et al. (2008) Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181: 4955-4964.
26. Jeyanathan M, Heriazon A, Xing Z, (2010) Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. Trends Immunol 31: 247-252.
27. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
28. Sable SB, Verma I, Khuller GK, (2005) Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine 23: 4175-4184.
29. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S, (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97: 13853-13858.
30. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, et al. (2008) A new recombinant Bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198: 1491-1501.
31. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, et al. (2010) The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4(+) and CD8(+) T cells in adults. Am J Respir and Crit Care Med 181: 1407-1417.
32. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ, (1999) Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67: 1702-1707.
33. Sali M, Di Sante G, Cascioferro A, Zumbo A, Nicolo C, et al. (2010) Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect Immun 78: 5202-5213.
34. Castanon-Arreola M, Lopez-Vidal Y, Espitia-Pinzon C, Hernandez-Pando R, (2005) A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis. Tuberculosis (Edinb) 85: 115-126.
35. Kumar P, Amara RR, Challu VK, Chadda VK, Satchidanandam V, (2003) The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model. Infect Immun 71: 1929-1937.
36. Fattorini L, Creti R, Nisini R, Pietrobono R, Fan Y, et al. (2002) Recombinant GroES in combination with CpG oligodeoxynucleotides protects mice against Mycobacterium avium infection. J Med Microbiol 51: 1071-1079.
37. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, et al. (2009) Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 27: 3267-3270.
38. Ferraz JC, Stavropoulos E, Yang M, Coade S, Espitia C, et al. (2004) A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect Immun 72: 6945-6950.
39. Wu Y, Woodworth JS, Shin DS, Morris S, Behar SM, (2008) Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8(+) T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection. Infect Immun 76: 2249-2255.
40. Giri PK, Verma I, Khuller GK, (2006) Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol Med Microbiol 47: 233-241.
41. Sable SB, Kalra M, Verma I, Khuller GK, (2007) Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol 122: 239-251.
42. Lefrancois L, Masopust D, (2002) T cell immunity in lymphoid and non-lymphoid tissues. Curr Opin Immunol 14: 503-508.
43. Di Rosa F, Pabst R, (2005) The bone marrow: a nest for migratory memory T cells. Trends Immunol 26: 360-366.
44. Olsen AW, Brandt L, Agger EM, van Pinxteren LAH, Andersen P, (2004) The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand J Immunol 60: 273-277.
45. Tree JA, Williams A, Clark S, Hall G, Marsh PD, et al. (2004) Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology. Clin Exp Immunol 138: 405-409.
46. Giri PK, Verma I, Khuller GK, (2006) Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect 53: 350-356.
47. Abolhassani M, Lagranderie M, Chavarot P, Balazuc AM, Marchal G, (2000) Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Infect Immun 68: 5657-5662.
48. Palendira U, Bean AGD, Feng CG, Britton WJ, (2002) Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. Infect Immun 70: 1410-1416.
49. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, et al. (2007) Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A 104: 12434-12439.
50. Gruppo V, Orme IM, (2002) Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis. Tuberculosis (Edinb) 82: 267-273.
51. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S, (2006) Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity. Vaccine 24: 443-451.
52. Giri PK, Sable SB, Verma I, Khuller GK, (2005) Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunol Med Microbiol 45: 87-93.
53. Aagaard C, Hoang TTKT, Izzo A, Billeskov R, Troudt J, et al. (2009) Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 (R) against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS ONE 4: e5930.
54. Mustafa AS, Lundin KE, Oftung F, (1993) Human T cells recognize mycobacterial heat shock proteins in the context of multiple HLA-DR molecules: studies with healthy subjects vaccinated with Mycobacterium bovis BCG and Mycobacterium leprae. Infect Immun 61: 5294-5301.
55. Sable SB, Goyal D, Verma I, Behera D, Khuller GK, (2007) Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. Eur Respir J 29: 337-346.
56. Dobos KM, Khoo KH, Swiderek KM, Brennan PJ, Belisle JT, (1996) Definition of the full extent of glycosylation of the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. J Bacteriol 178: 2498-2506.
57. Horn C, Namane A, Pescher P, Riviere M, Romain F, et al. (1999) Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern. J Biol Chem 274: 32023-32030.
58. Romain F, Horn C, Pescher P, Namane A, Riviere M, et al. (1999) Deglycosylation of the 45/47-kilodalton antigen complex of Mycobacterium tuberculosis decreases its capacity to elicit in vivo or in vitro cellular immune responses. Infect Immun 67: 5567-5572.
59. Ragas A, Roussel L, Puzo G, Riviere M, (2007) The Mycobacterium tuberculosis cell-surface glycoprotein Apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A. J Biol Chem 282: 5133-5142.
60. Beatty WL, Russell DG, (2000) Identification of mycobacterial surface proteins released into subcellular compartments of infected macrophages. Infect Immun 68: 6997-7002.
61. Lee JS, Shin SJ, Collins MT, Jung ID, Jeong YI, et al. (2009) Mycobacterium avium subsp paratuberculosis fibronectin attachment protein activates dendritic cells and induces a Th1 polarization. Infect Immun 77: 2979-2988.
62. Romain F, Laqueyrerie A, Militzer P, Pescher P, Chavarot P, et al. (1993) Identification of a Mycobacterium bovis BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria. Infect Immun 61: 742-750.
63. Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, et al. (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86: 83-88.
64. Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL, (1993) Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 91: 69-76.
65. Asanuma H, Thompson AH, Iwasaki T, Sato Y, Inaba Y, et al. (1997) Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods 202: 123-131.
66. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702.